A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 54, Issue 4, 2016, Pages 1509-1519

  Brody, Mark ^a   Liu, Enchi ^b   Di, Jianing ^b   Lu, Ming ^b   Margolin, Richard A ^c   Werth, John L ^d   Booth, Kevin ^d   Shadman, Anna ^b   Brashear, H Robert ^b   Novak, Gerald ^e  

^a Brain Matters Research   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Janssen Alzheimer Immunotherapy   (United States)

^d PFIZER INC   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alzheimer's disease; amyloid burden; bapineuzumab; biomarker; pharmacokinetics

Indexed keywords

AMYLOID; BAPINEUZUMAB; BIOLOGICAL MARKER; FLORBETAPIR F 18; LIVER ENZYME; PLACEBO; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BACKACHE; BEHAVIOR DISORDER; BRAIN EDEMA; BRAIN HEMORRHAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFUSION; FACE EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NAUSEA; NEUROIMAGING; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; BLOOD; CLINICAL TRIAL; DIAGNOSTIC IMAGING; FOLLOW UP; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84992153780     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160369     Document Type: Article

References (12)

1. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N,Weiss K,Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919
2. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11CPiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimers disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372
3. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimers disease. N Engl J Med 370, 322-333
4. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E, AAB-001 201/202, Investigators (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69, 1002-1010
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 34, 939-944
6. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali Doraiswamy P, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ, Skovronsky DM, AV45-A11 study group (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9, S72-S83
7. Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, ThiesW, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimers Association Research Roundtable Workgroup. Alzheimers Dement 7, 367-385
8. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24, 198-203
9. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial, Investigators (2009)Aphase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070
10. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimers disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol 11, 241-249
11. Ketter N, Brashear HR, Miaux Y, Purcell DD, Barkof F, Gass A, Collins P, Miloslavsky M, McGovern M, Morris K, Guenzler V, Arrighi HM. (2013) State of the art central review of brain magnetic resonance imaging (MRI) scans in Phase 3 clinical trials of intravenous bapineuzumab [abstract]. Neurology 80(7 Suppl), P06.035
12. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimers disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11, 597-604